Biofrontera (BFRI) Stock: Buy, Sell, or Hold?
BFRI - Biofrontera Inc. Common Stock
$1.04
-0.04 (-3.70%)
▼
5d:
-13.33%
30d:
-32.25%
90d:
+2.97%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When BFRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BFRI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BFRI is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.68
38.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BFRI is currently trading at $1.04, which is considered oversold relative to its 30-day fair value range of $1.17 to $1.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.4) compared to its historical average (4.5). Remarkably, the market is currently pricing in an annual earnings decline of 18.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+476.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is currently testing key support at $1.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+476.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.17 -
$1.54
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 476.9% below Wall St target ($6.00)
- WARNING: Composite score 53/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.17 -
$1.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.02
Resistance Level
$1.33
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.42
Wall Street Target
$6.00
(+476.9%)
Revenue Growth (YoY)
32.9%
Profit Margin
-13.8%
Valuation Discount vs History
-18.7% cheaper
PE vs Historical
2.4 vs 4.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.7%
(market-implied from PE analysis)
1-Year Target
$0.94
(-10%)
2-Year Target
$0.84
(-19%)
3-Year Target
$0.76
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→5)
$1.41
(+36%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.4 to 4.5
Stabilization Target:
$1.94
(+86.1%)
PE Expansion Potential:
+86.1%
Share & Embed Analysis
Last updated: October 02, 2026 3:04 AM ET
Data refreshes hourly during market hours. Next update: 4:04 AM
Data refreshes hourly during market hours. Next update: 4:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BFRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 55 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 53 HOLD |
